CD137 (human) (rec.) (His)

CHF 340.00
In stock
CHI-HR-200CD137-C02525 µgCHF 340.00
More Information
Product Details
Synonyms Tumor Necrosis Factor Receptor Superfamily Member 9; TNFRSF9; 4-1BB; 4-1BB Ligand Receptor T Cell; Antigen 4-1BB Homolog; T Cell Antigen ILA; CD137 Antigen; CDw137; ILA; MGC2172
Product Type Protein
Properties
Source/Host E. coli
Sequence

Human CD137 (aa 19-184) is fused at the C-terminus to a His-tag.

Crossreactivity Human
MW ~20kDa
Purity ≥95% (SDS-PAGE)
Endotoxin Content <1EU/mg protein (LAL test; Lonza).
Reconstitution Reconstitute in sterile water not less than 100μg/ml, which can then be further diluted to other aqueous solutions.
Formulation Lyophilized from a concentrated sterile solution containing 50mM Tris-HCl buffer (pH 8.0) and 500mM NaCl.
Other Product Data

NCBI reference AAH06196.1: CD137 (human)

Declaration Manufactured by Chimerigen.
Shipping and Handling
Shipping BLUE ICE
Short Term Storage +4°C
Long Term Storage -20°C
Handling Advice Avoid freeze/thaw cycles.
Use/Stability Stable for at least 1 year after receipt when stored at -20°C.
Working aliquots are stable for up to 3 months when stored at -20°C.
Documents
MSDS Inquire
Product Specification Sheet
Datasheet Download PDF

Human CD137 (4-1BB) is a costimulatory molecule of the tumor necrosis factor (TNF) receptor superfamily. The glycoprotein 4-1BB is expressed mainly on activated CD4+ and CD8+ T cells and binds to a high-affinity ligand (4-1BBL) expressed on several antigen-presenting cells such as macrophages and activated B cells. Upon ligand binding, 4-1BB is associated with the tumor receptor-associated factors (TRAF), the adaptor protein and mediates downstream signaling events including the activation of NF-κB and cytokine production. 4-1BB signaling either by binding to 4-1BBL or by antibody ligation delivers signals for T cell activation and growth as well as monocyte proliferation and B cell survival, and plays a important role in the amplification of T cell-mediated immune responses. In contrast, it can also enhance activation-induced T cell apoptosis when triggered by engagement of the TCR/CD3 complex. In addition, the 4-1BB/4-1BBL costimulatory pathway has been shown to augment secondary CTL responses to several viruses and increase antitumor immunity. 4-1BB is therefore a promising candidate for immunotherapy of human cancer.

© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.